clinical pearls for stroke patients in geriatric population
Post on 14-Apr-2017
60 Views
Preview:
TRANSCRIPT
Clinical Pearls for Stroke Prevention in Geriatric Population
Stroke Prevention Clinic
Objectives
• Stroke Prevention clinic scopes and services• Introduce the signs of stroke: newest FAST tool from Heart
and Stroke Foundation• The importance of secondary prevention after a TIA• Risk factors and management of stroke in geriatric population• Basic Antithrombotics principles and nursing implications• Common Post stroke positioning, mobility, and safety
Ontario Stroke Networks
• Ontario’s 11 regional stroke networks support the 14 LHINs
• Each stroke network is a collaborative partnership of health care organizations and providers
• Central LHIN Stroke Prevention Network:
1 Regional Stroke Center 5 Stroke Prevention Clinic
MHSPC
HumberSPC
NYGSPC
MSHSPC
SRHCSPC
MackenzieHealth
Regional Stroke Center
2008 Best Practice Recommendations for Stroke Care
Stroke prevention clinics Provide a comprehensive interdisciplinary approach to prevention of first or recurrent stroke, conduct detailed assessments by a range of healthcare disciplines, facilitate timely access to appropriate diagnostics and interventions, and provide education to patients and families. They also promote continuity of care between acute care facilities, the patient and their primary care providers”.
Stroke Prevention Clinic Model
Life style modifications and self-management: Link clients back to local Cardiovascular Rehab services
Comparison of Stroke Signs
(CIHI, 2011)
FAST TOOL
Risk of Stroke Within 90 Days of a TIA
Stroke Risk Factors
Non-modifiable Factors• Age over 60• Gender• Ethnic• Family history of Stroke• Family history of coronary artery
disease
Modifiable Factors• Hypertension• Dyslipidemia• Diabetes• Heart disease (ischemic, a-fib)• Carotid stenosis• Smoking• Obese• Inactivity• Excessive alcohol use• Sleep apnea: ↑HTN, ↑diabetes, ↑heart diseases,
↑carotid thickness, ↑depression• Stress
Risk Management in Stroke Prevention
• Blood pressure in geriatric population ≤150/90• Hemoglobin A1C <6.0% for non-diabetic • Hemoglobin A1C<7.0% for diabetic • LDL 50% reduction or below 2• Antiplatelet therapy • Treat atrial fibrillation• Treat sleep apnea with CPAP • Smoking cessation• Chronic disease management: Diabetes Education Center, Geriatric services, etc • Cardiac rehabilitation program and weight management• Other services: SLP, PT, OT, CCAC, vascular surgeon referral, etc
Oral Antithrombotic Therapy in Ischemic Stroke Patients
Oral Antithrombotic
Antiplatelet
Oral Anticoagulants
Vitamin K antagonists
DOACs
ASA
Aggrenox
Plavix
Useful facts about Direct-acting Oral anticoagulants
• Generally more favorable benefit/risk profile vs. warfarin, with sharply reduced intracranial bleeding
• Lack of antidote• Concomitant aspirin use increases bleeding• Don’t work for all• anticoagulation indications (e.g. prosthetic cardiac valves)• Each has different dosing and special issues• INRs / prothrombin times are not useful to monitor• Elderly patients do well on DOACs
Nursing implications • Short half-life require timely medication administration and
medication adherence• Missed Dose → ↑thrombotic event: administer the dose as soon as
possible on the same day. • Grapefruit juice may also increase plasma concentrations of
XARELTO and should be avoided (FDA, 2009)• Meal consumption increase Xarelto’s bioavailability for larger dose:
15 mg and 20 mg tablets should be taken with the evening meal • Avoid administration of Xarelto via a method that could deposit drug
directly into the proximal small intestine (e.g., feeding tube) which can result in reduced absorption and related drug exposure.
• Monitor signs and symptoms of bleeding, especially in clients with antiplatelets /NASIDs
References• CIHI. (2011). Warning signs and symptoms of stroke. Retrieved from
http://www.cihi.ca/cihi-ext-portal/internet/en/document/types+of+care/hospital+care/acute+care/RELEASE_12JULY12_FIG2
• Food and Drug Administration (2009). Review of Xarelto. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf
• Gottschalk, R. (2014). Sleep apnea and stroke. Retrieved from http://www.heartandstroke.on.ca/atf/cf/%7B33C6FA68-B56B-4760-ABC6-D85B2D02EE71%7D/GOTTSCHALK-Sleep-Apnea-and-Stroke-F1-05.pdf
Hart, R. G. (2014). New oral anticoagulants for atrial fibrillation: 4 things that primary professional should know. Retrieved from http://www.heartandstroke.on.ca/atf/cf/%7B33C6FA68-B56B-4760-ABC6-D85B2D02EE71%7D/GOTTSCHALK-Sleep-Apnea-and-Stroke-F1-05.pdf
• Hear and Stroke Foundation. (2014). Stroke signs. Retrieved from http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483937/k.ED98/Stroke__Stroke_Warning_Signs.htm?gclid=CjwKEAjw9bKpBRD-geiF8OHz4EcSJACO4O7Tgi3l5qeh9QC4vOc-mg0nXUR1UQe2OBS-7KbXECjOMRoC_Vfw_wcB
• Food and Drug Administration ( 2011). Xarelto (Rivaroxabab) tablet label. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf
top related